Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.

Autor: Furl R; Section of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Scarsi KK; Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA., Sayles H; College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA., Anderson M; College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA., Ofimboudem JD; Treatment Action Group, New York, USA., Weld ED; Division of Infectious Diseases, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Waked I; Hepatology Department, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt., Gomaa A; Hepatology Department, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt., Al-Khatib A; Hepatology Department, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt., Elshobary FM; National Liver Institute, Menoufia University, Shebin El-Kom, Egypt., Desalegn H; Department of Internal Medicine, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia., Fisseha H; Department of Internal Medicine, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia., Solomon S; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Mehta S; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Owen A; Department of Pharmacology and Therapeutics, Centre of Excellence in Long-Acting Therapeutics (CELT), University of Liverpool, Liverpool, UK., Rannard S; Department of Chemistry, Centre of Excellence in Long-Acting Therapeutics (CELT), University of Liverpool, Liverpool, UK., Thomas DL; Division of Infectious Diseases, Division of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Swindells S; Section of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Jazyk: angličtina
Zdroj: Journal of viral hepatitis [J Viral Hepat] 2024 Nov 15. Date of Electronic Publication: 2024 Nov 15.
DOI: 10.1111/jvh.14031
Abstrakt: Despite available curative treatments, global rates of hepatitis C virus (HCV) infection persist with significant burden in low- and middle-income countries (LMICs). Long-acting (LA) antiviral products are in development. This study explored the challenges and opportunities in LA-HCV treatment across three LMICs: Egypt, Ethiopia and India. The survey focused on understanding barriers and facilitators to treatment, with emphasis on LA treatment preferences. Four-hundred respondents completed a survey including demographics, HCV treatment history and preferences for injections, implants and microarray patches (MAPs) compared to pills. Overall, 78% of respondents were willing to receive injections, 43% were willing to receive implants and 55% were willing to receive MAPs. Marked heterogeneity in acceptability of non-oral treatments was observed. Among respondents who had not previously received HCV treatment, 94%, 43%, and 75% were willing to receive injections, implants, or MAPs, respectively. In contrast, among those already cured by oral HCV treatment, 61%, 40% and 43% were willing to receive injections, implants or MAPs. Other characteristics associated with willingness to receive an injection included urban residence, younger age, male sex, higher education level and taking pills for any reason (all results p < 0.001). The most common concern for all LA modalities was lack of effectiveness. Prior experience with injection or implant increased willingness to receive any LA modality (p < 0.001). Coupled with a point-of-care HCV diagnostic test, availability of and willingness to receive HCV treatment delivered by a LA formulation could simplify and expand treatment access in LMICs and contribute towards global HCV elimination goals.
(© 2024 The Author(s). Journal of Viral Hepatitis published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: